Scintigraphic evaluation of lymphoma: a comparative study of ⁶⁷Ga citrate and ¹¹¹In bleomycin

Sequential whole body scans with both ⁶⁷Ga citrate and ¹¹¹In bleomycin were performed for 14 patients undergoing staging for Hodgkin's disease or other lymphomas. A comparison of these scans gave a sensitivity in detecting the pathologically proved tumor sites of 84% for ⁶⁷Ga citrate and only 56% for ¹¹¹In bleomycin. In 12 patients, the gallium scan demonstrated the lesions more clearly; in the others, the uptake of the two radionuclides was equal. In no case was a clinically diagnosed or histologically proved lesion identified by ¹¹¹In bleomycin that was not also demonstrated by ⁶⁷Ga citrate. ¹¹¹In bleomycin does not complement the ⁶⁷Ga citrate scan in the scintigraphic evaluation of lymphomas.